무라벨 어레이 시스템 시장 : 기술, 용도, 최종 용도별 - 세계 예측

Global Label-free Array Systems Market will register over 7.2% CAGR from 2024 to 2032, driven by the upsurge of point-of-care (POC) diagnostics. The demand for rapid, accurate, and user-friendly diagnostic tools is increasing as healthcare professionals seek solutions that offer real-time analysis without complex sample preparation or labeling. This trend is fueled by the need for on-the-spot diagnostics that provide immediate results and facilitate timely decision-making.

Label-free array systems offer enhanced diagnostic capabilities, supporting the broader adoption of point-of-care testing. Quoting an instance, in January 2024, HORIBA Medical launched the HELO 2.0 high-throughput automated hematology platform, now CE-IVDR approved and pending US FDA clearance. This new system offers flexible, modular configurations for mid to large-scale labs, integrating advanced technologies for improved efficiency and eco-friendlier operation.

The label-free array systems market is segmented based on technology, application, end-use, and region.

The bio-layer interferometry segment will evince a noteworthy CAGR between 2024 and 2032, due to the increasing need for high-resolution molecular interactions and real-time analytical capabilities. As R&D in life sciences advances, there is a growing emphasis on obtaining precise, label-free data to better understand biomolecular processes. The shift is driven by the desire for more accurate and reproducible results in complex biological assays, leading to higher adoption of technologies that offer direct and detailed measurement without the need for additional labeling steps.

By 2032, the protein interface analysis segment will grab a sizeable label-free array systems market share, attributed to the growing need for an understanding of protein dynamics. Researchers and pharmaceutical companies are focused on elucidating complex protein behaviors and interactions to advance drug discovery and development. Label-free technologies offer a non-invasive, real-time approach to studying these interactions, providing valuable insights without the interference of additional labeling agents. This ability to directly analyze protein interfaces with high accuracy and resolution is thriving the adoption of label-free systems.

Through 2032, North America label-free array systems market will show an impressive CAGR, due to investments in life sciences research and a strong focus on technological innovation. The research institutions and biotechnology companies are leading advancements in molecular biology, requiring advanced analytical tools for efficient data acquisition. The increasing emphasis on personalized medicine and genomics research is strengthening the need for label-free technologies that deliver real-time results. Government funding and a collaborative research environment support the growing product adoption across North America, favoring market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing drug discovery and development activities
    • 3.2.1.2 Advancements in biotechnology and life sciences research
    • 3.2.1.3 Rising cases of chronic and infectious diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High initial investment cost
    • 3.2.2.2 Complexity and technical expertise requirements
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Surface plasmon resonance
• 5.3 Bio-layer interferometry
• 5.4 Cellular dielectric spectroscopy
• 5.5 Microcantilever
• 5.6 Scanning kelvin nanoprobe
• 5.7 Enthalpy array
• 5.8 Atomic force microscopy
• 5.9 Other technologies

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug discovery
• 6.3 Protein interface analysis
• 6.4 Antibody characterization and development
• 6.5 Protein complex and cascade analysis
• 6.6 Detection of disease biomarkers
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical & biotechnology companies
• 7.3 Academic & research institutes
• 7.4 Contract research organizations
• 7.5 Hospitals and clinics
• 7.6 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Agilent Technologies, Inc.
• 9.2 Becton, Dickinson and Company
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 Corning Incorporated
• 9.5 Danaher Corporation
• 9.6 F. Hoffmann-La Roche AG
• 9.7 Illumina, Inc.
• 9.8 Merck KGaA
• 9.9 Meso Scale Diagnostics (MSD)
• 9.10 Nanion Technologies
• 9.11 Pall Corporation
• 9.12 PerkinElmer, Inc.
• 9.13 Sartorius AG
• 9.14 Siemens Healthineers AG
• 9.15 Thermo Fisher Scientific Inc.